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Abstract
Background: Prostate cancer (PCa) is one of the leading causes of cancer-related mortality and morbidity in the
aging male population and represents the most frequently diagnosed malignancy in men around the world. The Deltex
(DTX)-3-like E3 ubiquitin ligase (DTX3L), also known as B-lymphoma and BAL-associated protein (BBAP), was originally
identified as a binding partner of the diphtheria-toxin-like macrodomain containing ADP-ribosyltransferase-9 (ARTD9),
also known as BAL1 and PARP9. We have previously demonstrated that ARTD9 acts as a novel oncogenic survival factor
in high-risk, chemo-resistant, diffuse large B cell lymphoma (DLBCL). The mono-ADP-ribosyltransferase ARTD8, also
known as PARP14 functions as a STAT6-specific co-regulator of IL4-mediated proliferation and survival in B cells.
Methods: Co-expression of DTX3L, ARTD8, ARTD9 and STAT1 was analyzed in the metastatic PCa (mPCa) cell lines PC3,
DU145, LNCaP and in the normal prostate luminal epithelial cell lines HPE and RWPE1. Effects on cell proliferation,
survival and cell migration were determined in PC3, DU145 and/or LNCaP cells depleted of DTX3L, ARTD8, ARTD9,
STAT1 and/or IRF1 compared to their proficient control cells, respectively. In further experiments, real-time RT-PCR,
Western blot, immunofluorescence and co-immunoprecipitations were conducted to evaluate the physical and
functional interactions between DTX3L, ARTD8 and ARTD9.
Results: Here we could identify DTX3L, ARTD9 and ARTD8 as novel oncogenic survival factors in mPCa cells. Our
studies revealed that DTX3L forms a complex with ARTD8 and mediates together with ARTD8 and ARTD9 proliferation,
chemo-resistance and survival of mPCa cells. In addition, DTX3L, ARTD8 and ARTD9 form complexes with each other.
Our study provides first evidence that the enzymatic activity of ARTD8 is required for survival of mPCa cells. DTX3L and
ARTD9 act together as repressors of the tumor suppressor IRF1 in mPCa cells. Furthermore, the present study shows
that DTX3L together with STAT1 and STAT3 is implicated in cell migration of mPCa cells.
Conclusions: Our data strongly indicate that a crosstalk between STAT1, DTX3L and ARTD-like
mono-ADP-ribosyltransferases mediates proliferation and survival of mPCa cells. The present study further
suggests that the combined targeted inhibition of STAT1, ARTD8, ARTD9 and/or DTX3L could increase the efficacy of
chemotherapy or radiation treatment in prostate and other high-risk tumor types with an increased STAT1 signaling.
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Introduction
Prostate cancer (PCa) is a clinically and molecularly het-
erogeneous disease that is characterized by its aggressive
metastasization [1-3]. PCa is one of the leading causes of
cancer-related mortality and morbidity in the aging male
population and represents the most frequently diagnosed
malignancy in men around the world [1,2]. Patients
diagnosed with PCa and de novo metastatic tumors
are generally treated with androgen deprivation therapy
(ADT) since the growth of PCa is originally androgen-
dependent [1,2]. However, ADT is primarily palliative,
nearly all patients will eventually develop the androgen-
independent and highly metastatic forms of PCa termed
castration-resistant PCa (CRPC) [1,2]. Docetaxel-based
chemotherapy remains the first-line treatment for men
diagnosed with CRPC providing modest survival and pal-
liative benefits [1,2,4]. Unfortunately, chemotherapy resist-
ance develops in more than half of all CRPC patients and
remains the major obstacle in treatment of CRPC [1,2,4].
Attempts to improve survival of cancer patients largely
depend on strategies to target the tumor cell resistance. A
common feature of PCa is the dependence on nuclear fac-
tor kappa B and the activated signal transducer and activa-
tors of transcription (STAT). Several studies have shown
that STAT3 and STAT5 are required for cell growth, pro-
liferation, survival, invasion and metastasis of many PCa
subtypes [1,2,5-10]. In addition, STAT1 has been recently
identified as a proto-oncogene product in a variety of can-
cers, including metastatic PCa (mPCa) [11-23]. A recent
study has shown that 29% of clinical human mPCa’s ana-
lyzed, constitutively expressed STAT1 and IFN-stimulated
genes in vivo [12]. STAT1 has been initially suggested to
act exclusively as a suppressor of tumorigenesis, by acti-
vating growth-inhibitory and pro-apoptotic signaling in
tumor cells, mainly mediated by interferon response
factor (IRF)-1 [24-27].
IFNγ/STAT1 signaling is mediated through activation
of IFNγ receptor and Janus kinases (JAK) 1 and 2 that lead
to tyrosine phosphorylation of STAT1 on Y701, homodi-
merization and translocation of STAT1 to the nucleus
where it induces the transcription of IFNγ-stimulated
genes, including the tumor suppressor IRF1 [28]. Phos-
phorylation on Y701 enhances the phosphorylation on
S727 in the transactivation domain of STAT1α [29-31].
Several studies have demonstrated that chemotherapeu-
tic agents, such as doxorubicin, docetaxel or anthracyclines
enhance the expression of STAT1 and its activation in
chemo-resistant cancer cells [11,12,14,32]. STAT1 has been
shown to be required for the observed P-glycoprotein-
independent chemo-resistance towards docetaxel [15].
Several mechanisms have been reported to mediate do-
cetaxel resistance in metastatic CRPC, such as those
mediated by the P-glycoprotein/ABC multidrug trans-
porter family [33-35], the STAT1-AKT1-clusterin axis
with its pro-survival functions [15,36] and via constitu-
tive activation of the CXCR4, ERK1/2 and c-Myc signal-
ing loop [37]. STAT1 has therefore been suggested as a
potential target for chemo-sensitization of aggressive
tumors that constitutively overexpress IFNγ/STAT1-
dependent pathways [12].
We have previously demonstrated that the ADP-
ribosyltransferase-9 (ARTD9), also known as B-aggressive
lymphoma protein (BAL1) and PARP9, acts as a novel
oncogenic survival factor in high-risk, chemo-resistant, host
response (HR) sub-types of diffuse large B-Cell lymphoma
(HR-DLBCL) and as a crucial negative and positive
co-regulator of IFNγ/STAT1-signaling [23]. ARTD9 is an
inactive mono-ADP-ribosyltransferase belonging to the
intracellular Diphteria toxin-like glutamate/aspartate-
specific mono- and polymerizing-ADP-ribosyltransferase
(ARTD) family (also known as PARPs) [38] that also in-
cludes the active mono-ADP-ribosyltransferase ARTD8
(also known as PARP14) [38-41]. Like ARTD9, ARTD8
contains several evolutionary conserved macrodomains,
which have been recently shown to act as binding mod-
ules for free and protein-linked mono- or poly-ADP-
ribose [42-44]. ARTD9 counteracts the IFNγ-dependent
anti-proliferative and pro-apoptotic IFNγ-STAT1-IRF1-
p53 axis and induces an oncogenic switch in high-risk
HR-DLBCL that transforms STAT1 from a tumor suppres-
sor to a proto-oncogene [23]. As a consequence, ARTD9
mediates proliferation, survival and chemo-resistance in
HR-DLBCL [23]. ARTD8 has been shown to mediate
survival in c-Myc-driven Burkitt lymphoma-like tumors
in vivo and in multiple myeloma in vitro [39,45,46].
ARTD8 functions as a STAT6-specific co-regulator of IL4-
mediated gene expression and is suggested to be involved
in mediating IL4-induced proliferation and protection of B
cells against apoptosis following irradiation or growth fac-
tor withdrawal [39-41].
The Deltex (DTX)-3-like E3 ubiquitin ligase (DTX3L),
also known as B-lymphoma and BAL-associated protein
(BBAP), was originally identified as a binding partner of
ARTD9 [47-49]. DTX3L is overexpressed in subtypes of
high-risk chemotherapy-resistant aggressive HR-DLBCL
with an active host inflammatory response and tightly
associated with intrinsic IFNγ signaling and constitutive
activity of STAT1 [23,47,48]. Recent studies have provided
first evidence that DTX3L and ARTD9 are also overex-
pressed in a variety of solid cancers, such as Ewing
tumor or cervical carcinomas [46,48-52]. The DTX3L
and ARTD9 genes are located in a head-to-head orientation
on chromosome 3q21 and share the same bidirectional
IFNγ-responsive promoter [48]. DTX3L monoubiquitinates
histone H4 lysine 91 and has been suggested to protect cells
exposed to DNA damaging agents [53]. Targeted inhibition
of DTX3L has been therefore suggested to increase the
efficacy of DNA-damaging chemotherapeutic agents or
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radiation treatment [53]. However, the role of DTX3L in
PCa, especially in the context of STAT1-signaling, has
not been investigated.
In this study we identify DTX3L, ARTD8 and ARTD9 as
novel oncogenic survival factors in androgen-independent
CRPC-like mPCa cells. We demonstrate that DTX3L me-
diates together with ARTD8 and ARTD9 proliferation,
chemo-resistance and survival in mPCa cells, indicating
a functional and physical crosstalk between DTX3L and
macrodomain-containing mono-ADP-ribosyltransferases in
mPCa.
Results and discussion
DTX3L, ARTD8 and ARTD9 are constitutively overexpressed
in mPCa associated with increased IFNγ/STAT1-signaling
The DTX3L gene and all three genes encoding macrodo-
main containing ARTD proteins (ARTD7-9) are located
in the same evolutionary conserved gene cluster [48]. In
order to investigate whether constitutive overexpression
of DTX3L, ARTD8 and ARTD9 is associated with mPCa
we analyzed their expression levels in the PCa cell lines
PC3, DU145 and LNCaP [54-59], and in the normal
prostate luminal epithelial cell lines HPE and RWPE1.
PC3 and DU145 cells are androgen-refractory mPCa cell
lines and are commonly used as CRPC models [60-62].
PC3 and DU145 cells have a high and moderate tumori-
genic potential, respectively [58-62], and are highly inva-
sive compared to the poorly tumorigenic LNCaP cells
[62-65]. Contrary to the LNCaP cells, the PC3 and DU145
cells have been previously described to display enhanced
basal levels of STAT1 activity and to express high levels of
IL6 [15,66]. Both, PC3 and DU145 cells have been recently
described to have an autocrine IL6 loop while LNCaP cells
do not have any detectable IL6 secretion [66]. Our immu-
noblot analysis of DTX3L, ARTD8 and ARTD9, STAT1
and pSTAT1, revealed that DTX3L, ARTD8 and ARTD9
are constitutively overexpressed in the mPCa cell lines
PC3 and DU145 but not in the JAK1-negative [67,68]
LNCaP cells or in HPE and RWPE1 cells (Figure 1A).
We have previously demonstrated that overexpression
of DTX3L and ARTD9 is tightly associated with intrinsic
IFNγ-signaling and constitutively active STAT1 in HR-
DLBCL [23]. We therefore examined whether constitu-
tive overexpression of endogenous DTX3L, ARTD9 and
ARTD8 is associated with STAT1 or alternatively with
another STAT signaling pathway in mPCa cells. Our im-
munoblot analysis of DTX3L, ARTD8, ARTD9, STAT1,
pSTAT1, STAT2, pSTAT2, STAT3α, STAT3αβ, pSTAT3α,
STAT5, pSTAT5, STAT6 and pSTAT6 expression re-
vealed that constitutive overexpression of DTX3L, ARTD8
and ARTD9 is indeed associated with enhanced STAT1
(pSTAT1-S727)-signaling and an autocrine IL6 loop [66]
(Figure 1B-D and Additional file 1: Figure S1A-C). ARTD8
and ARTD9 were absent in LNCaP cells (Figure 1A, B and
Additional file 1: Figure S1A, C). Subsequent experiments
revealed that the expression of both DTX3L and ARTD9
but not of ARTD8 is dependent on JAK1 (Additional file 1:
Figure S1D). A recent study has provided first evidence
that expression of ARTD9 and DTX3L is induced by IL6
and strongly associated with an autocrine IL6-signaling
loop in mPCa cells [66]. IL6 mainly activates STAT3, how-
ever under certain conditions, STAT1 can also be activated
by IL6, [69-72]. Subsequent control experiments revealed
that depletion of STAT3 in PC3 cells inhibits the expres-
sion of ARTD9 and DTX3L (Additional file 1: Figure S1E).
Thus, constitutive overexpression of DTX3L and ARTD9
is likely mediated through an IL6/JAK1-STAT1:STAT3-
signaling pathway in PC3 and DU145 cells in the ab-
sence of IFNγ, while further up-regulated through an
IFNγ/JAK1-STAT1:STAT1-mediated signaling pathway.
DTX3L was still expressed in LNCaP cells, though to
a much lesser extend (Figure 1A, B Additional file 1:
Figure S1A), suggesting that DTX3L can be regulated in a
cell type-specific manner, independently of ARTD9, IFNγ/
STAT1 and IL6/STAT3 signaling in mPCa cells.
Both, PC3 and DU145 cells showed high basal levels of
transcriptionally active pSTAT1α(pS727) in the nucleus
(Figure 1B, C, Additional file 1: Figure S1B and Additional
file 2: Figure S2A), while PC3 cells showed enhanced basal
levels of activated STAT1α/β(pY701) (Figure 1A-C and
Additional file 1: Figure S1B, C). The JAK1-negative LNCaP
cell line only shows low basal levels of transcriptionally
active pSTAT1α(pS727) but did not show any enhanced
basal levels of activated STAT1α/β(pY701) (Figure 1B and
Additional file 2: Figure S2B). Phosphorylation on S727 in
the transactivation domain of STAT1α can also occur in-
dependently of STAT1 tyrosine phosphorylation [73], indi-
cating that heterodimerization with other (constitutively)
tyrosine phosphorylated STATs such as STAT3 may be re-
quired for nuclear translocation of STAT1 in absence of
phosphorylation on Y701 [69,74]. However, basal levels of
constitutively active STAT1 in PC3 and DU145 cells are
not comparable with those previously observed in the
P-glycoprotein independent STAT1-AKT1-clusterin me-
diated docetaxel-resistant residual cell lines PC3-DR and
DU145-DR [15,33,36,75-77]. The basal levels of active
STAT1 (pSTAT1α-S727 and pSTAT1α/β-Y701) observed
in PC3-DR or DU145-DR are highly similar to those pre-
viously observed in chemo-resistant HR-DLBCL cell lines
such as SUDHL7 [23].
We have previously demonstrated that ARTD9 inhibits
the transcriptional activation of tumor suppressor IRF1
in HR-DLBCL [23]. We therefore tested whether the ex-
pression of IRF1 is negatively correlated with the expres-
sion of DTX3L and ARTD9 in mPCa. Indeed, the tumor
suppressor IRF1 is constitutively up-regulated in absence
of DTX3L and ARTD9 in LNCaP cells, while down-
regulated in presence of DTX3L and ARTD9 in PC3 and
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DU145 cells (Figure 1D and Additional file 2: Figure S2C).
These observations suggest that DTX3L and ARTD9 might
act together as transcriptional repressors of the IRF1 gene
in mPCa cells.
In agreement with previous studies in HR-DLBCL
[23,48], DTX3L and ARTD9 were mainly localized in the
cytoplasm whereas only small subfractions show nuclear
localization (Figure 1E). Conversely, ARTD8 was evenly
distributed in the nucleus and cytoplasm in these cells
(Figure 1E). DTX3L is a nucleocytoplasmic shuttling pro-
tein and complex formation between DTX3L and ARTD9
in the nucleus has been suggested to facilitate the nuclear
export of ARTD9 by DTX3L [48]. However, our subse-
quent siRNA-knockdown experiments revealed that en-
dogenous DTX3L does not facilitate the nuclear export of
ARTD9 in PC3 cells. ARTD9 was mainly localized in the
cytoplasm in both PC3-siMock and PC3-siDTX3L cells
(Additional file 3: Figure S3A, B and Additional file 4:
Figure S4A, B). The same pattern was observed for DTX3L
in PC3-siMock and PC3-siARTD9 cells (Additional file 3:
Figure S3A, C and Additional file 4: Figure S4A, C),
strongly indicating that the nuclear shuttling of ARTD9 is
mainly regulated by other factors, and thus, the previously
observed nuclear export of ectopically overexpressed fluor-
escent protein-tagged-ARTD9 by ectopically overexpressed
fluorescent protein-tagged-DTX3L [48] most likely rep-
resents a mechanism highly specific to the cell type and
stimuli.
Crosstalk among DTX3L, ARTD8 and ARTD9 mediates
proliferation in mPCa cells
In order to investigate whether a crosstalk among DTX3L,
ARTD8 and ARTD9 mediates proliferation in mPCa
cells we first analyzed the proliferation of cells depleted
of DTX3L, ARTD8 or ARTD9 using siRNA (Additional
file 5: Figure S5A, B) in presence or absence of IFNγ.
IFNγ is known to inhibit the proliferation of p53-negative,
androgen-refractory mPCa cells [78,79]. These experiments
revealed that knockdown of DTX3L or ARTD9 in PC3 cells
strongly inhibits proliferation when compared to control
cells (Figure 2A, B), whereas knockdown of ARTD8 only
showed a minor effect on proliferation (Figure 2C). As
expected, knockdown of DTX3L or ARTD9 in LNCaP
cells did not affect cell growth in LNCaP cells (data not
shown). We next analyzed the effect on proliferation upon
double knockdown of ARTD8/DTX3L, ARTD9/DTX3L or
ARTD8/ARTD9 in PC3 cells. These analyses revealed that
ARTD8 acts synergistically or additively together with
DTX3L and ARTD9 in proliferation, strongly suggesting a
functional crosstalk between ARTD8, DTX3L and ARTD9
(Figure 2D, E). No significant additional effects on prolifer-
ation were observed in siDTX3L/siARTD9 double knock-
down cells indicating that DTX3L and ARTD9 regulate
the same signaling pathway(s) in proliferation (Figure 2F).
DTX3L was originally identified as an ADP-ribosylation
independent binding partner of ARTD9, interacting with
the catalytic domain of ARTD9 [47]. Moreover, a recent
study suggested that DTX3L interacts through ARTD9
with ARTD1 (also known as PARP1) in a DNA damage
and poly-ADP-ribosylation-dependent manner [80]. We
therefore investigated whether DTX3L forms endogenous
complexes with ARTD8 under normal physiological con-
ditions. Indeed, our co-immunoprecipitation studies in
PC3 cells revealed that endogenous DTX3L forms strong
complexes with ARTD8 and ARTD9 (Figure 2G, J and
Additional file 5: Figure S5C, D). However, endogenous
DTX3L barely interacted with ARTD1 under normal phy-
siological conditions (Figure 2G). No interaction was
observed with ARTD2 (also known as PARP2) (Figure 2G).
Subsequent co-immunoprecipitation experiments with
endogenous ARTD8, ARTD9 and other ARTDs in PC3
cells revealed that endogenous ARTD9 strongly inter-
acts with ARTD8 (Figure 2H, I and Additional file 5:
Figure S5D, F) and also interacts to a lesser extent with
other active mono-ADP-ribosyltransferases (Additional
file 5: Figure S5E). ARTD9 only interacted weakly with
ARTD1 (Figure 2H), whereas no interaction was ob-
served with ARTD2 (Figure 2H). These experiments
(See figure on previous page.)
Figure 1 DTX3L is constitutively overexpressed together with ARTD8 and ARTD9 in mPCa associated with increased IFNγ/STAT1
signaling. (A) Immunoblot analyses of untreated p53-negative, mPCa cell lines PC3 and DU145, androgen-sensitive and JAK1-negative LNCaP cell
line and of the immortalized normal prostate luminal epithelial cell lines HPE and RWPE1. The HR-DLBCL-SUDHL7 cell line constitutively expressing
DTX3L, ARTD9 and ARTD8 [23] was used as a positive control. Whole cell extracts were separated by SDS PAGE, blotted and subsequently probed with
antibodies for DTX3L, ARTD1, ARTD8 and ARTD9 pSTAT1(Y701) and tubulin. (B) Immunoblot analyses of STAT1-signaling in p53-negative mPCa cell
lines PC3 and DU145 and in the androgen-sensitive and JAK1-negative LNCaP cell line treated with or without IFNγ or IFNαβ. PC3, DU145 and LNCaP
cells were treated with or without IFNγ (200 U/ml) or IFNαβ (50 U/ml each) for 2 h and then whole cell extracts separated by SDS PAGE and subsequently
probed with antibodies for DTX3L, ARTD9, STAT1, pSTAT1(Y701), pSTAT1(S727) and tubulin. The immunoblots are representative of at least three
independent experiments. (C) Immunofluorescence microscopy analyses and sub-cellular localization of endogenous STAT1, pSTAT1-(pY701)
and pSTAT1-(pS727) in PC3 cells, in presence or absence of 1000 U/ml IFNγ. Original magnification × 400. Images are representative of at least
three independent experiments. (D) Immunoblot analyses of basal expression levels of IRF1 in PC3, DU145 and LNCaP cell lines. Whole cell
extracts were separated by SDS PAGE and subsequently probed with antibodies for IRF1 and tubulin. The immunoblot is representative of at
least three independent experiments. (E) Immunofluorescence microscopy analyses and sub-cellular localization of endogenous DTX3L, ARTD8
and ARDT9 in PC3 cells, in presence or absence of 1000 U/ml IFNγ. Original magnification × 400. Images are representative of at least three
independent experiments.
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revealed that the observed interactions between ARTD9
and active mono-ADP-ribosyltransferases are mediated by
(mono)-ADP-ribosylation (Figure 2H, I and Additional
file 5: Figure S5D, E) and thus very likely mediated
through their macrodomains. Several studies have dem-
onstrated that the interaction between macrodomain-
containing ARTDs and (mono)-ADP-ribosylated proteins,
including active mono-ARTD enzymes, such as ARTD8
and ARTD10 (also known as PARP10), is mediated through
their macrodomains [44,80,81]. Conversely, the observed
interaction between DTX3L and ARTD8 or ARTD9 is
not dependent on ADP-ribosylation ([47], Figure 2J and
Additional file 5: Figure S5D), indicating that DTX3L
could form different (mono)-ADP-ribosylation dependent
and (mono)-ADP-ribosylation independent complexes with
ARTD8 and ARTD9. Given that ARTD8 does not function
as a coactivator for STAT1 [40] it is very likely that different
DTX3L-ARTDx complexes simultaneously exist and do act
in distinct signaling pathways.
Crosstalk among DTX3L, ARTD8 and ARTD9 mediates
chemo-resistance and survival in mPCa cells in an
ADP-ribosylation-dependent manner
In order to strengthen our previous observation in DLBCL
[23], we subsequently analyzed the chemo-resistance and
survival in PC3 cells depleted of either DTX3L, ARTD8 or
ARTD9 in the presence or absence of IFNγ and/or doce-
taxel. Indeed we found that DTX3L, ARTD8 and ARTD9
mediate survival and chemo-resistance in mPCa cells
(Figure 3A and Additional file 6: Figure S6A-F). To ad-
dress whether there is a functional crosstalk between
DTX3L, ARTD8 and ARTD9 in mediating survival and
chemo-resistance, we performed double knockdown stud-
ies in PC3 cells. Interestingly, upon simultaneous deple-
tion of ARTD8/DTX3L, ARTD9/DTX3L and ARTD8/
ARTD9, IFNγ could enhance the sensitivity towards doce-
taxel in the absence of DTX3L or ARTD9. These results
strongly suggest that both DTX3L and ARTD9, but not
ARTD8, counteract the IFNγ-dependent anti-proliferative
and pro-apoptotic IFNγ-STAT1-IRF1 axis [23] (Figure 3B).
No significant additional effects on survival and chemo-
resistance were observed in siDTX3L/siARTD9 double
knockdown cells indicating that DTX3L and ARTD9 regu-
late the same signaling pathways in survival and chemo-
resistance (Figure 3B). Together, these results indicate
that there is a functional crosstalk between DTX3L,
ARTD8 and ARTD9 in survival and chemo-resistance in
mPCa cells. ARTD8 does not influence STAT1 signaling
directly but through other mechanisms. A recent study
in mice has provided first evidence that ARTD8 func-
tions as a STAT6-specific co-regulator of IL4-mediated
gene expression and is involved in IL4-induced prolifera-
tion and protection of B cells against apoptosis following
irradiation or growth factor withdrawal [39]. Although no
clear correlation between STAT6 expression or activity
and ARTD8 could be observed in mPCa cell lines, it is
very likely that ARTD8 might act together with DTX3L as
a STAT6-specific survival factor in mPCa cells. STAT6
has been recently shown to act as a survival factor and to
enhance mPCa progression [82]. Alternatively, ARTD8
might act together with DTX3L independently of STAT6
signaling in these cell lines.
Our finding of a (mono)-ADP-ribosylation-dependent
interaction between ARTD8 and ARTD9 strongly sug-
gests that the enzymatic activity of mono-ADP-ribosyl
transferases is required for this interaction. Thus, we an-
alyzed the effects of the enzymatic activity of ARTD8 or
other ARTDs on survival and proliferation of mPCa cells.
A recent study suggested that ARTD9 and ARTD1 physic-
ally and functionally interact and together mediate survival
in response to genotoxic stress [80]. In order to test this
hypothesis we treated ARTD8- or ARTD9-depleted PC3
cells in presence or absence of docetaxel with the ARTD1/
2-specific inhibitors Olaparib and Veliparib [83-86] or with
the more ARTD7/8-specific inhibitors DPQ and TIQ-A
[83-85]. ARTD8- or ARTD9-depleted cells treated with
Olaparib and Veliparib only showed a minor increase in
cell death when compared to control cells. (Figure 3C).
(See figure on previous page.)
Figure 2 Crosstalk among DTX3L, ARTD8 and ARTD9 mediates proliferation in PC3 cells. (A-F) Cell proliferation analyses of PC3-siMock,
PC3-siDTX3L, PC3-siARTD8, PC3-siARTD9 single knockdown cells (A-C) and PC3-siDTX3L/siARTD8, PC3 siDTX3L/siARTD9 or PC3-siARTD9/siARTD8
double knockdown cells (D-F) in presence or absence of IFNγ (200 U/ml) was assessed by the trypan blue exclusion assay. Relative cell proliferation
and cell numbers are presented as mean from three independent experiments performed in triplicates. All error bars represent the SE. Statistical
analysis was performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001. (G) Co-immunoprecipitation analyses of endogenous DTX3L
and ARTD family members in PC3 cells. PC3 cells were stimulated for 1 h with or without IFNγ (200 U/ml) and endogenous DTX3L complexes were
then co-immunoprecipitated, separated on SDS PAGE, blotted and subsequently probed with antibodies for DTX3L, ARTD1 (positive control), ARTD2,
ARTD8 and ARTD9. (H) Interaction of endogenous ARDT9 and ARTD1 or ARTD8 is mediated by (mono)-ADP-ribosylation. PC3 cells were stimulated for
1 h with IFNγ (200 U/ml) and endogenous ARTD9-ARTDx complexes subsequently co-immunoprecipitated in presence or absence of 5 mM
mono-ADP-ribose using an anti-ARTD9 antibody. Complexes were then separated on SDS PAGE, blotted and subsequently probed with antibodies
against endogenous ARTD1 (positive control), ARTD2, ARTD8 and ARTD9. (I, J) Interaction between endogenous DTX3L and ARTD8 or ARTD9 is
independent of (mono)-ADP-ribosylation. Endogenous DTX3L-ARTD8/9 complexes were co-immunoprecipitated from extracts of PC3 cells in presence
or absence of 5 mM mono-ADP-ribose using either an anti-ARTD9 (I) or an anti-DTX3L (J) antibody. Complexes were then separated on SDS PAGE,
blotted and subsequently probed with antibodies against endogenous ARTD8, ARTD9 and DTX3L.
Bachmann et al. Molecular Cancer 2014, 13:125 Page 7 of 24
http://www.molecular-cancer.com/content/13/1/125
Figure 3 (See legend on next page.)
Bachmann et al. Molecular Cancer 2014, 13:125 Page 8 of 24
http://www.molecular-cancer.com/content/13/1/125
Remarkably, treatment with DPQ and TIQ-A strongly
increased cell death in ARTD9-depleted cells when com-
pared to control cells (Figure 3C). Conversely, in ARTD8-
depleted cells we did not observe an increase in cell death
upon DPQ and TIQ-A treatment when compared to con-
trol cells (Figure 3C), indicating that one of the definitive
targets of DPQ and TIQ-A is the enzymatic activity of
ARTD8. Moreover, we did not observe any functional
crosstalk between ARTD1 and ARTD8 or ARTD9 n PC3
cells under the tested conditions (Figure 3C). In line with
these observations, overexpression of active ARTD8 wild
type in PC3 cells enhanced survival in siMock cells and
rescued the effects on cell survival in siARTD8 knock-
down cells. In contrast, overexpression of a catalytically
inactive ARTD8 mutant form in ARTD8-depleted PC3
cells did not increase cell survival in siMock cells or
siARTD8 knockdown cells (Additional file 6: Figure S6G).
These results strongly suggest that the enzymatic activity
of ARTD8 is required for the survival of mPCa cells.
DTX3L and ARTD9 mediate proliferation, chemo-resistance
and survival in mPCa cells in a STAT1-dependent manner
Several studies strongly suggest that STAT1α activates anti-
proliferative and pro-apoptotic genes (i.e. mediated through
the IFNγ-STAT1-IRF1-p53 axis) while concomitantly acti-
vating anti-apoptotic-pro-survival pathways (i.e. mediated
through the STAT1-IRF2/BCL2-axes) [23,87,88]. In addi-
tion, overexpression of STAT1β, the antagonistic iso-
form of STAT1α, increases the growth rate of cells and
their resistance to drug-induced apoptosis and cell cycle
arrest by repressing STAT1α target genes such as p21
and IRF1 [87]. Our previous study has demonstrated that
ARTD9-mediated cell proliferation, chemo-resistance and
cell survival in HR-DLBCL is dependent on STAT1 [23].
In order to examine whether depletion of STAT1 might
inhibit the pro-apoptotic and/or anti-proliferative IFNγ-
STAT1-IRF1-axis in absence of DTX3L or ARTD9 we
next analyzed cell proliferation (Figure 4A-C) and cell sur-
vival (Figure 4D) defects in PC3 cells simultaneously de-
pleted of DTX3L/STAT1, ARTD8/STAT1 and ARTD9/
STAT1. Indeed, depletion of STAT1 did not further inhibit
cell proliferation, chemo-resistance and cell survival in the
absence of ARTD9 or DTX3L, when compared to the
single knockdown cells (Figure 4A, B, D). However, the
observed proliferation defects and the increase in cell
death upon depletion of DTX3L or ARTD9 could not
be fully rescued by simultaneous depletion of DTX3L/
STAT1 and ARTD9/STAT1, when compared to single
knockdown and control cells (Figure 4A-D). However,
depletion of STAT1 alone strongly affected cell prolifera-
tion (Figure 4A, B), chemo-resistance and cell survival
(Figure 4D), indicating that STAT1 itself is required for
cell proliferation, chemo-resistance and cell survival. Con-
versely, cell proliferation and survival of ARTD8-depleted
cells is even more inhibited upon additional depletion of
STAT1 (Figure 4C, D), clearly indicating that STAT1 and
ARTD8 do not act together in the same signaling path-
way. Given that depletion of STAT1 alone strongly af-
fected cell proliferation and survival, but did not further
inhibit cell proliferation and survival in the absence of
ARTD9 or DTX3L (Figure 4A, B), indicates that DTX3L
and ARTD9 together with STAT1 act in the same sig-
naling pathways.
Taken together these results suggest that both DTX3L
and ARTD9 mediate cell proliferation, survival and chemo-
resistance of mPCa cells in a STAT1-dependent manner
whereas ARTD8 enhances survival and chemo-resistance
independently of STAT1 (Figure 4A-D).
DTX3L and ARTD9 repress expression of the tumor
suppressor IRF1 in PCa cells
ARTD9 can bind to the IRF1-promoter and together with
STAT1β inhibits the transcription of the IRF1 gene, thereby
counteracting the IFNγ-dependent anti-proliferative and
pro-apoptotic IFNγ-STAT1-IRF1-p53 axis in high-risk HR-
DLBCL [23]. We therefore investigated whether DTX3L
and/or ARTD9 function as transcriptional repressors of
IRF1 and regulate STAT1 signaling in PCa cells. Our
current study demonstrates that DTX3L and ARTD9
act together as repressors of the tumor suppressor IRF1
(See figure on previous page.)
Figure 3 Crosstalk among DTX3L, ARTD8 and ARTD9 mediates chemo-resistance and survival in PC3 cells and is dependent on
ADP-ribosylation. (A) Cell viability analyses of PC3-siMock, PC3-siDTX3L, PC3-siARTD8 and PC3-siARTD9 single knockdown cells were assessed by
the trypan blue exclusion assay. Cells were treated as indicated with IFNγ and/or docetaxel (DT) and counted after 48 h, NT: not treated, CT:
control treatment (solvent). Values represent the means of three independent experiments, and the error bars represent the SE. Statistical analysis
was performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001 (B) Cell viability analyses of PC3-siMock, PC3-siDTX3L/siARTD8,
PC3-siDTX3L/siARTD9 or PC3-si ARTD9/siARTD8 double knockdown cells were assessed by the trypan blue exclusion assay. Cells were treated as
indicated with IFNγ and/or docetaxel (DT) and counted after 48 h, NT: not treated, CT: control treatment (solvent). Values represent the means of
three independent experiments, and the error bars represent the SE. Statistical analysis was performed using the Student's t test. *P < 0.05,
**P < 0.001 and ***P < 0.0001. (C) Cell viability analyses of PC3-siMock, PC3-siDTX3L, PC3-siARTD8 and PC3-siARTD9 single knockdown cells
treated in presence or absence of docetaxel (DT) (0.5 nM) with the ARTD1/2-specific inhibitors Olaparib (1 μM) and Veliparib (1 μM) or with the
more ARTD7/8-specific inhibitors DPQ (7.5 μM) and TIQ-A (7.5 μM) were assessed by the trypan blue exclusion assay. Values represent the means
of three independent experiments performed in triplicate, and the error bars represent the SE. Statistical analysis was performed using the
Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
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in mPCa. The basal IRF1 protein and mRNA expression
levels were strongly increased in PC3 cells depleted of
DTX3L or ARTD9 in absence of IFNγ (Figure 5A-C and
Additional file 7: Figure S7C). The IRF1 protein and
mRNA expression was further increased in PC3 cells
depleted of DTX3L or ARTD9 upon IFNγ treatment
(Figure 5A-C and Additional file 7: Figure S7C). Subse-
quent IRF1-promoter-driven luciferase reporter assays
in PC3 cells showed that overexpression of DTX3L or
ARTD9 together with STAT1β down-regulates the IRF1-
promoter-driven luciferase reporter (Additional file 7:
Figure S7D-F). Moreover, co-overexpression of all three
proteins together (DTX3L, ARTD9 and STAT1β) syner-
gistically down-regulated the IRF1-promoter-driven
luciferase reporter (Additional file 7: Figure S7G). To-
gether, these results suggest that ARTD9 and DTX3L
cooperate and act as transcriptional repressors by forming a
ternary complex with STAT1β. It remains to be investigated
whether DTX3L might monoubiquitinate histone H4 lysine
91 on the IRF1-promoter and thereby inhibits the transcrip-
tion of the IRF1 gene. In addition, our knockdown experi-
ments demonstrate that DTX3L and ARTD9 positively
regulate the expression of each other on their own gene
expression level, though to a different extent (Figure 5A,
B, D). Depletion of DTX3L strongly inhibited the expres-
sion of ARTD9 whereas depletion of ARTD9 inhibited the
expression of DTX3L to a minor extent. We have previ-
ously shown that ARTD9 can bind to its own bidirectional
promoter [23]. Thus, DTX3L and ARTD9 positively regu-
late each other directly through their shared bidirectional
promoter.
To confirm these observations, we next analyzed the
effect of IRF1 on proliferation and cell survival by either
depletion or overexpression of IRF1 in PCa cells. Ex-
ogenous overexpression of human IRF1 in PC3 cells
(Additional file 8: Figure S8A) revealed that the pres-
ence of IRF1 indeed strongly inhibited proliferation of
PC3 cells (Figure 5E). In line with this, knockdown of
IRF1 enhanced the proliferation of PC3 (Figure 5F and
Additional file 8: Figure S8B, C) and of LNCaP cells
(Figure 5G and Additional file 8: Figure S8D), although
to a lesser extent in the JAK1-negative LNCaP cell line
(Figure 5G). Several studies suggest that phosphorylation
and/or acetylation of IRF1 is required for full transcriptional
activity of IRF1 [89-91]. Tyrosine phosphorylation and
probably also acetylation of IRF1 appears to be dependent
on active IFNγ/JAK1 signaling [89,91]. Subsequent sur-
vival assays with cells depleted of IRF1 revealed that IRF1
does not inhibit survival of mPCa cells (Additional file 8:
Figure S8E), strongly indicating that other STAT1-
dependent target genes are involved and/or required for
the DTX3L/ARTD9-mediated effects on survival of mPCa
cells. Future studies will be required in order to identify
the target genes involved in these processes and elucidate
the exact molecular mechanisms.
DTX3L interacts with the IFNGR complex and
antagonistically regulates together with ARTD9 the
phosphorylation of STAT1 on Y701 in mPCa cells
Since our previous studies showed that ARTD9 en-
hances phosphorylation of both isoforms of STAT1 on
Y701 we tested whether DTX3L might function together
with ARTD9 in regulating the phosphorylation of STAT1
on Y701 in mPCa cells. Surprisingly, these experiments re-
vealed that DTX3L and ARTD9 antagonistically regulate
the phosphorylation of both STAT1 isoforms STAT1α and
STAT1β, on Y701 in mPCa cells. ARTD9 also stimulated
phosphorylation of STAT1 on Y701 (Figure 6A, C) whereas
DTX3L strongly inhibited phosphorylation of STAT1 on
Y701 (Figure 6B, D). However, the observed effects of
ARTD9 on STAT1 phosphorylation are less pronounced
than previously observed in HR-DLBCL [23]. In contrast to
their P-glycoprotein-independent chemo-resistant variants
PC3-DR or DU145-DR [15,33,36,75-77] both PC3 and
DU145 cells do not have high basal levels of constitu-
tively tyrosine phosphorylated STAT1 (pSTAT1α(Y701)
and pSTAT1β(Y701) and are sensitive towards doce-
taxel [15,33,36,75-77]. Thus, the siDTX3L- and siARTD9-
mediated effects on STAT1-signaling are most likely much
higher in the PC3-DR or DU145-DR cells [15] and are
therefore more comparable with the effects observed in
HR-DLBCL. Moreover, since DTX3L and ARTD9 regulate
each other on their gene expression level (Figure 5A, B
and D) the observed antagonistic effects are tightly bal-
anced and might explain why the effects are not com-
pletely visible in the knockdown cells.
Our previous study has provided preliminary evidence
that ARTD9 interacts with the IFNGR-receptor complex
(See figure on previous page.)
Figure 4 DTX3L- and ARTD9-mediated proliferation, chemo-resistance and survival in PC3 cells is dependent on STAT1. (A-C) Cell
proliferation analyses of PC3-siMock, PC3-siSTAT1, PC3-siSTAT1/siDTX3L (A), PC3-siSTAT1/siARTD8 (B), or PC3-siSTAT1/siARTD9 (C), double
knockdown cells in presence or absence of IFNγ (200 U/ml) were assessed by the trypan blue exclusion assay. Relative cell proliferation and cell
numbers are presented as mean from three independent experiments performed in triplicate, the error bars represent the SE. Statistical analysis
was performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001. (D) Cell viability analyses of a PC3-siMock, PC3-siSTAT1 single
knockdown, and PC3-siSTAT1/siDTX3L PC3-siSTAT1/siARTD8 or PC3-siSTAT1/siARTD9 double knockdown cells were assessed by the trypan blue
exclusion assay. Cells were treated as indicated with IFNγ and/or docetaxel (DT), NT: not treated, CT: control treatment (solvent). Values represent
the means of three independent experiments performed in triplicates, and the error bars represent the SE. Statistical analysis was performed using
the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
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and thereby stimulates directly or indirectly the kinase ac-
tivity of JAK1/2 [23]. Indeed, our co-immunoprecipitation
studies revealed that endogenous DTX3L interacts with
activated STAT1-containing IFNGR-receptor complexes
in the cytoplasm (Figure 6E, F) and forms together with
ARTD9 complexes with STAT1 in the nucleus (Additional
file 8: Figure S8F). No interaction with the tyrosine
phosphatases PTPN1 and PTPN2, both known to de-
phosphorylate pSTAT1 on Y701 [92-94], was observed
(Figure 6F). Our observations strongly suggest that DTX3L
and ARTD9 might antagonistically regulate the JAK1/2 kin-
ase activity and thereby antagonistically influence the nu-
clear activities of both STAT1α and STAT1β. Thus, DTX3L
and ARTD9 seem to be required for the fine-tuning of
STAT1-signaling, particularly in tumorigenesis. Moreover,
since both DTX3L and ARTD9 are target genes of STAT1
[23,48] the suggested antagonistic and cooperative activities
of DTX3L and ARTD9 may represent a general negative
and positive feedback loop in STAT1-signaling. Due to the
fact that ARTD9 and DTX3L are regulating each other
on the level of gene expression it is quite difficult to ex-
perimentally address the exact molecular mechanisms
underlying the proposed antagonism between them.
The observed effect on STAT1 tyrosine phosphorylation
might be regulated through (mono)-ubiquitinylation and/or
mono-ADP-ribosylation. We have previously shown that
the interactions between ARTD9 and STAT1α/β are
mediated through macrodomains and dependent on
ADP-ribosylation [23]. However, we did not find any
direct evidence that STATs are mono-ADP-ribosylated
in vivo. Thus, it remains to be investigated whether
(mono)-ubiquitinylation and/or mono-ADP-ribosylation
is involved in this process.
DTX3L mediates cell migration of mPCa cells in a STAT1
and/or STAT3-dependent manner
A recent study has provided first evidence that ARTD9
might be associated with lymphocyte migration and may
promote the dissemination of malignant B cells in high-
risk DLBCL in vivo [48,95]. Ectopic overexpression of
ARTD9 in an ARTD9 and DTX3L-negative DLBCL cell
line derived from low risk DLBCL tumor strongly en-
hanced the migration in vitro when compared to control
cells [48]. In order to investigate whether endogenous
DTX3L or ARTD9 are required for the migration of mPCa
cells we analyzed the migration potential of PC3 cells de-
pleted of DTX3L and ARTD9 using the classical scratch
wound healing assay for adherent cell lines. Surprisingly,
upon depletion of DTX3L, but not ARTD9 or ARTD8,
cell migration was impaired in PC3 and DU145 cells
(Figure 7A-C and Additional file 9: Figure S9A-F). These
observations are in contrast to the previous study, which
did not address the expression level of DTX3L in the
ARTD9 ectopically overexpressing DLBCL cell line [48].
We next investigated whether the observed effects of
DTX3L on migration of mPCa cells is dependent on
STAT1. Besides its role in mediating tumor survival and
growth, STAT3 plays a crucial role in tumor migration,
invasion and metastasis [7,69] and recent studies pro-
vided preliminary evidence that STAT1 is involved in
migration of mPCa cells [20,21]. In order to evaluate
whether cell migration is also dependent on STAT1 we
investigated the migration potential of cells depleted of
STAT1 or both STAT1 and DTX3L. These experiments
showed that the observed effect is indeed dependent on
STAT1-signaling (Figure 7D, E and Additional file 10:
Figure S10A, B, E). Migration of PC3 and DU145 cells
was not further impaired upon double knockdown of
STAT1 and DTX3L when compared to single depletion
of DTX3L or STAT1, strongly indicating that DTX3L and
STAT1 act together in the same pathway(s) (Figure 7D, E
and Additional file 10: Figure S10A, B, E). Control experi-
ments revealed that IRF1 does not affect migration of
mPCa cells (Additional file 10: Figure S10D), suggesting
that the IFNγ/IRF1 axis is not involved in cell migration.
The fact that depletion of ARTD9 and IRF1 did not
affect cell migration suggests that DTX3L acts in STAT1-
signaling pathways in an ARDT9/IFNγ-independent
(See figure on previous page.)
Figure 5 DTX3L and ARTD9 repress tumor suppressor IRF1 expression in mPCa cells. (A and B) Immunoblot analyses of the tumor
suppressor gene product IRF1. PC3-siMock, PC3-siDTX3L (A) or PC3-siARTD9 (B) single knockdown cells were treated with or without IFNγ (200 U/ml)
for 6 h and then whole cell extracts separated by SDS PAGE, blotted and subsequently probed with antibodies for ARTD9, DTX3L, IRF1, IRF7 and tubulin.
The immunoblots are representative of at least three independent experiments. (C) Quantification of IRF1 levels shown in Figure 5A, B. IRF1 levels were
normalized to tubulin. Values represent the means of three independent experiments. (D) Quantification of ARTD9 and DTX3L protein levels in
PC3-siMock, PC3-siDTX3L and PC3-siARTD9 single knockdown, respectively, as represented in Figure 5A, B. ARTD9 and DTX3L protein levels were
normalized to tubulin. Values represent the means of three independent experiments. (E) Cell proliferation analyses of PC3-CMVprom-empty-control
and PC3-CMVprom-IRF1 cells were assessed in presence or absence of IFNγ (100U/ml) by the trypan blue exclusion assay. Relative cell proliferation and
cell numbers are presented as means of three independent experiments performed in triplicates. (F) Cell proliferation analyses of PC3-siMock, PC3-siIRF1
and PC3-siARTD9 single knockdown cells were assessed in presence or absence of IFNγ (200 U/ml) by the trypan blue exclusion assay. Relative cell
proliferation and cell numbers are presented as means of three independent experiments performed in triplicate. (G) Cell proliferation analyses of
LNCaP-siMock and LNCaP-siIRF1 single knockdown cells were assessed by the trypan blue exclusion assay. Relative cell proliferation and cell numbers
are presented as means of two independent experiments performed in triplicate. All error bars shown in A to G represent the SE. Statistical analysis was
performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
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Figure 6 DTX3L interacts with the IFNGR complex and together with ARTD9 antagonistically regulates the phosphorylation of STAT1
on Y701 in PC3 cells. (A and B) Immunoblot analyses of STAT1-signaling in PC3-siMock, PC3-siDTX3L (A), and PC3-siARTD9 (B) single knockdown
cells. PC3-siMock, PC3-siDTX3L or PC3-siARTD9 single knockdown cells were treated with or without IFNγ (200 U/ml) for 2 h and then whole cell extracts
separated by SDS PAGE, blotted and subsequently probed with antibodies for STAT1, pSTAT1(Y701), pSTAT1(S727) and tubulin. The immunoblots are
representative of at least three independent experiments. (C and D) Quantification of pSTAT1(Y701) and pSTAT1(S727) levels shown in Figure 5A, B.
pSTAT1(Y701) and pSTAT1(S727) levels were normalized to tubulin and STAT1. Values represent the mean of three independent experiments,
and the error bar represents the SE. Statistical analysis was performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
(E and F) Co-immunoprecipitation analyses of endogenous DTX3L-IFNGR complexes in PC3 cells: Endogenous DTX3L/IFNGR complexes were
co-immunoprecipitated using an anti-DTX3L antibody. Complexes were then separated on SDS PAGE, blotted and subsequently probed with
antibodies against endogenous DTX3L, ARTD9, STAT1, IFNGR1, JAK1, JAK2, PTPN1 and PTPN2.
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manner. The observed DTX3L-dependent effects on migra-
tion might be therefore mediated by the constitutive nuclear
activity of pSTAT1α(pS727) homo- or heterodimers.
Indeed, the observed impairment of cell migration upon
DTX3L/STAT1 knockdown is in line with the cell migra-
tion analyzed upon depletion of STAT3 (Figure 8A and
Figure 7 DTX3L but not ARTD9 or ARTD8 mediates together with STAT1 cell migration of PC3 cells. (A-E) PC3-siMock, PC3-siDTX3L (A),
PC3-siARTD9 (B), PC3-siARTD8 (C), PC3-siSTAT1 (D) single knockdown cells and PC3-siDTX3L/siSTAT1 (E) PC3-double knockdown cells were seeded
into 6-well plates and treated as described in Material and Methods. At 0, 12, 24, and 36 h photographs were made and quantified as described in Ma-
terial and Methods. Values represent the mean of three independent experiments and the error bars represent the SE. Statistical analysis was per-
formed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
Bachmann et al. Molecular Cancer 2014, 13:125 Page 15 of 24
http://www.molecular-cancer.com/content/13/1/125
Additional file 9: Figure S9F), which was used as positive
control in this set of experiments. Subsequent control ex-
periments revealed that the observed effect might be in-
deed also dependent on STAT3-signaling (Figure 8B-D
and Additional file 10: Figure S10F-H). No further sig-
nificant inhibition was observed neither in siSTAT1/
siSTAT3, siDTX3L/siSTAT3 double knockdown cells nor
in siDTX3L/siSTAT1/siSTAT3 triple knockdown cells
when compared to siDTX3L, siSTAT1 or siSTAT3 single
knockdown cells, strongly indicating that DTX3L, STAT1
and STAT3 act in the same pathway(s) (Figure 8B-D and
Additional file 10: Figure S10F-H). DTX3L might function
in a non-canonical STAT1:STAT3 heterodimer-mediated
signaling pathway in migration of mPCa cells.
Together, our in vitro cell migration analyses strongly
indicate that DTX3L together with STAT1 is crucial for
proliferation and survival but might also be required
together with STAT1 for the metastasization and dis-
semination of androgen-refractory mPCa cells in vivo.
Conclusions
We have identified the E3 ubiquitin ligase DTX3L and the
macrodomain-containing mono-ADP-ribosyltransferases
ARTD8 and ARTD9 as novel oncogenic survival factors in
androgen-independent mPCa cells. Constitutive overex-
pression of DTX3L and ARTD9 is mediated through both
IL6/JAK1-STAT1:STAT3- and IFNγ/JAK1-STAT1:STAT1-
mediated signaling pathways (Figure 9A). Together with
ARTD8 and ARTD9, DTX3L mediates proliferation,
chemo-resistance and survival in mPCa cells (Figure 9B).
Our study demonstrates that DTX3L and ARTD9 cooper-
ate as repressors of the tumor suppressor IRF1 in mPCa
cells (Figure 9C). However, since depletion of IRF1 does
only positively affect proliferation but not cell survival, the
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Figure 8 DTX3L-mediated cell migration of PC3 cells might also be dependent on STAT3. (A-F) PC3-siSTAT3 single knockdown cells (A),
PC3-siDTX3L/siSTAT3 (B), PC3-siSTAT1/siSTAT3 (C) double knockdown cells and PC3-siDTX3L/siSTAT1/siSTAT3 (D) triple knockdown cells were
seeded into 6-well plates and treated as described in Material and Methods. At 0, 12, 24, and 36 h photographs were made and quantified as
described in Material and Methods. Values represent the mean of three independent experiments and the error bars represent the SE. Statistical
analysis was performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
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DTX3L/ARTD9-mediated effects on survival observed in
the mPCa cell lines used in this study are only partially
dependent on IRF1 in these cells. Thus, the DTX3L/
ARTD8 and DTX3L/ARTD9 target genes, which act to-
gether with IRF1 in mediating survival and/or prolifera-
tion, respectively, remain to be identified in future studies.
Our results suggest that both DTX3L and ARTD9
may influence the nuclear activities of both STAT1α and
STAT1β by antagonistically regulating the tyrosine phos-
phorylation of STAT1 on Y701 and therefore being re-
quired for the fine-tuning of STAT1-signaling, particularly
in tumorigenesis (Figure 9C). Conversely, both DTX3L and
ARTD9 cooperate in the transcriptional repression of IRF1.
Thus, the exact molecular mechanisms are much more
complicated and remain to be elucidated in future studies.
In addition to their regulatory roles in STAT1-mediated
chemo-resistance, both DTX3L and ARTD9 could also
be directly involved in editing or inhibiting the IFNγ-
dependent host immune response against tumor cells
through the termination of IFNγ-mediated gene expres-
sion and the inhibition of the extrinsic IFNγ-induced
anti-proliferative and pro-apoptotic STAT1-IRF1-X-axis.
Alternatively, the observed crosstalk between DTX3L/
ARTD9 and ARTD8 in absence of IFNγ strongly indicates
that DTX3L/ARTD9 and ARTD8 act independently of
IFNγ-mediated signaling in cell proliferation and survival.
Our data provide first evidence for a crosstalk between
mono-ubiquitin-ligase(s) and mono-ADP-ribosyltransfer
ases that mediates proliferation and survival in mPCa
and thus suggest that these processes might be tightly
regulated by mono-ADP-ribosylation and (mono)-ubiqui-
tination. However, the potential (mono)-ubiquitinylation
activity of DTX3L and the exact molecular mechanisms
of ARTD8-mediated mono-ADP-ribosylation underlying
the observed crosstalk remain to be addressed in future
studies.
Our in vitro study suggests that DTX3L together with
STAT1 might be required for the metastasis and
Figure 9 Proposed working models for the postulated crosstalk among DTX3L, ARTD8 and ARTD9 in chemotherapy-resistant mPCa
cells. (A) Constitutively active IL6/STAT3-signaling and enhanced IFNGR-JAK1/2-STAT1- signaling in chemotherapy-resistant mPCa cells, including
CRPC-like cells causes overexpression of DTX3L and ARTD9, which in turn, further stimulates their own expression through a positive feedback
loop. (B) Crosstalk between DTX3L/ARTD9-STAT1 and ARTD8-STAT6-signaling pathways is required for proliferation and cell survival of
chemotherapy-resistant mPCa cells, including CRPC-like cells. (C) Similar to the situation in HR-DLBCL, DTX3L and ARTD9, together with STAT1β
repress the transcriptional activation of the tumor suppressor IRF1 and other anti-proliferative and pro-apoptotic genes while together with
STAT1α both, DTX3L and ARTD9 might activate genes required for cell proliferation and survival of mPCa cells. (D) Overexpression of DTX3L but
not ARTD8 or ARTD9 also mediates cell migration of mPCa cells, dependent on STAT1 and STAT3-signaling. DTX3L might form migration-specific,
ARTD9-independent STAT1 homodimer or non-canonical STAT1/STAT3 heterodimer complexes.
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dissemination of metastatic CRPC cells in vivo (Figure 9D).
Thus, further studies need to be carried out in order to
determine whether simultaneous ectopic co-overexpression
of ARTD9 together with wild type or enzymatic mutant
forms of DTX3L and/or ARTD8 in xenograft prostate tu-
mors confer docetaxel resistance and/or enhance metastasis
in vivo.
Taken together, our study suggests that the combined
targeted inhibition of STAT1, ARTD8, ARTD9 and/or
DTX3L could increase the efficacy of chemotherapy or ra-
diation treatment in prostate and other high-risk tumor
types with an increased STAT1- and STAT3-signaling. For
instance, the combination of classical therapeutic drugs
with highly ARTD8 or DTX3L-specific inhibitors and
drugs specifically targeting STAT1 or the macrodomains
of ARTD9 might provide a novel therapeutic strategy to
increase the sensitivity of PCa cells towards classical ther-
apy, and thus pave the way to develop novel personalized
therapeutic strategies for patients suffering from aggres-
sive PCa.
Material and methods
Cell culture, transfections, luciferase reporter assays and
generation of stable cell lines
The CRPC-like mPCa cell lines PC3 and DU145 [54,61]
as well as the JAK1-negative, poorly tumorigenic cell line
LNCaP [54,61,67,68] were all purchased from ATCC
(American Type Culture Collection). They were cultured
in 50% Ham’s-F12 and 50% of RPMI-1640, Glutamax-I,
10 mmol/l HEPES with 10% FCS, and Penicillin and
Streptomycin. Transfections of cells with plasmid DNA
were performed with Fugene HD, Extreme gene 9 and
HP transfection reagents (Roche Applied Science) accord-
ing to the manufacturers’ protocols. Transfections of siRNA
oligos were performed with Lipofectamine RNAimax
(Invitrogen) or Extreme gene siRNA reagents (Roche
Applied Science) according to manufacturers’ protocols.
For complementation of PC3-siARTD8 knockdown cells
with non-degradable cDNAs of active ARTD8 wild type or
catalytically inactive ARTD8 mutant form, transfections of
cells with cDNAs were performed 24 h after transfection of
siRNA oligos. Cells were generally treated/pretreated with
siRNA oligos for 36-48 h before the assays were performed.
Plasmids
Human DTX3L cDNA was amplified by PCR from a B-cell
Lymphoma cDNA library and cloned into the corre-
sponding expression vectors (EF1a-promoter driven) using
BamHI-NotI respectively. The mouse ARTD8 cDNA was a
generous gift from Dr. M. Boothby (Vanderbilt University
School of Medicine, Nashville, TN, USA) and cloned
into the corresponding expression vectors (EF1a-promoter
driven) using BamHI-NotI respectively. The enzymati-
cally inactive ARTD8 mutant form containing two
mutations in the evolutionary conserved catalytic triad
motif (H-Y-I < − > Q-Y-T; aa 1698H-Q and aa1798I-T)
[38,96] was generated by PCR and verified by sequen-
cing. The siRNA oligos were purchased from Qiagen.
The corresponding siRNA sequences are listed in
Additional file 11: Table S1. Expression vectors for STAT1
and ARTD9 are described in [23]. Expression vectors
for human IRF1 were purchased from Addgene. hIRF1-
prom-luciferase reporter vectors were a nice gift from
Dr. R. Pine (Public Health Research Institute, Newark,
NJ, USA).
Reagents
Human recombinant interferons were all purchased from
PeproTech or kindly provided by Dr. J. Pavlovic (Institute
of Medical Virology, University of Zurich, Switzerland),
docetaxel and doxorubicin were purchased from SIGMA.
Tosyl-activated Dynabeads were purchased from Invitro-
gen. ADP-ribose was purchased from SIGMA.
Interaction assays, immunoblot analyses and
immunofluorescence microscopy
Membrane, cytoplasmic, nuclear, and whole cell extracts
were prepared as described in [23,97,98]. For immunopre-
cipitation membrane and cytoplasmic extract fractions
were re-mixed. Co-immunoprecipitation assays were
performed as described previously [23,97,98] using the
following DTX3L and ARTD9 specific antibodies: rabbit
anti-DTX3L antibody Cat.No.: D9644-01B), rabbit anti-
DTX3L antibody (Bethyl Laboratories, Inc., Cat.No.: A300-
833A,) and rabbit anti-ARTD9 antibody (Chemicon/EMD
Millipore, Cat.No.: AB10619, Lot No.: LV1409682). All anti-
bodies used for immunoprecipitation analysis were cova-
lently coupled to tosyl-activated Dynabeads (Invitrogen)
according to the manufacturers’ protocols. Immunoblot
analysis and immunofluorescence microscopy were per-
formed as described in [23,97,98] using the following pri-
mary antibodies: Rabbit anti-DTX3L (US Biological, Cat.
No.: D9644-01B), rabbit anti-DTX3L, (Bethyl Laboratories,
Inc., Cat.No.: A300-833A), rabbit anti-ARTD9 (EMD
Millipore, Cat.No.: AB10618), rabbit anti-ARTD9 anti-
body (EMD Millipore, Cat.No.: AB10619), mouse anti-
ARTD2 (EMD Millipore, Cat.No.: MABE18), rabbit
anti-ARTD3 (Aviva Systems Biology Corp., Cat.No.:
OAAB03449), rabbit anti-ARTD10 (Aviva Systems Biology
Corp., Cat.No.: ARP42810_P050), rabbit anti-ARTD12
(Aviva Systems Biology Corp., Cat.No.: OAAB03451), rabbit
anti-ARTD11 (Abgent, Cat.No.: AP6297a), rabbit anti-
ARTD13 (GeneTex, Cat.No.: N3C2), anti-STAT1α/β (Rab-
Mab, Epitomics, Cat.No.: 2728–1), anti-pSTAT1α/β(Y701)
(RabMab, Epitomics, Cat.No.: 2825–1), anti-pSTAT1α
(S727) (RabMab, Epitomics, Cat.No.: 3324–1), anti-STAT2
(RabMab, Epitomics, Cat.No.: 1513–1), anti-STAT3α (Rab-
Mab, Epitomics, Cat.No.: 3566–1), anti-pSTAT3α(S727)
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(RabMab, Epitomics, Cat.No.: 2236–1), anti-STAT5 (Rab-
Mab, Epitomics, Cat.No.: 1289–1), anti-pSTAT5(S726)
(RabMab, Epitomics, Cat.No.: 5734–1), anti-STAT6 (Rab-
Mab, Epitomics, Cat.No.: 1505–1), anti-PTPN1 (RabMab,
Epitomics, Cat.No.: 3774–1), anti-PTPN2 (RabMab, Epi-
tomics, Cat.No.: 5790–1), anti-pJAK1 (RabMab, Epito-
mics, Cat.No.: 6518–1), anti-JAK1 (RabMab, Epitomics,
Cat.No.: 2856–1), anti-IFNGR1 (RabMab, Epitomics, Cat.
No.: 5697–1), anti-IFNGR2 (RabMab, Epitomics, Cat.No.:
7932–1), anti-IRF1 (RabMab, Cell Signaling Technology,
Cat.No.: 8478), anti-STAT3α/β (RabMab, Cell Signaling
Technology, Cat.No.: 12640), rabbit anti-pSTAT2(Y690)
(St. Cruz Biotechnology, Inc., Cat.No.: sc-21689-R), rabbit
anti-pSTAT6(Y641) (St. Cruz Biotechnology, Inc., Cat.No.:
sc-101808) and mouse anti-tubulin (SIGMA, Cat.No.: T5
618). The rabbit anti-ARTD8 antibody was a generous gift
from Dr. Avraham Raz (Karmanos Cancer Institute, School
of Medicine, Wayne State University, Detroit, Michigan
48201, USA [99]). Immunofluorescence analysis was per-
formed with an automated inverted research microscope
system (Leica DMI6000B, Leica Microsystem). Composite
images were generated by Adobe Photoshop software.
Quantification of immunoblots was performed using the
GelEval software (FrogDance Software Inc.) and mean
value ± SE was calculated and plotted into graphs using
the GraphPad Prism 5 software (GraphPad Software, Inc.).
Survival and proliferation assays
Cell viability and proliferation was assessed by trypan blue
exclusion assays as described in [23]. For the cell viability
and proliferation assays cells were seeded at 0.2 × 106 cells/
well (PC3 and DU145) and 0.1 × 105 cells/well (LNCaP) in
6 well dishes 8-12 h prior to initiation of treatment and
then incubated for 24 h in the presence of PBS, DMSO
(mock-treated), IFNγ (200 U/ml) or docataxel (0.5-1 nM),
ARTD/PARP inhibitors Olaparib (1 μM), Veliparib (1 μM),
DPQ or TIQ-A (7.5 μM). Relative cell viability/prolifera-
tion and cell numbers are presented as means from three
(PC3 and DU145) or two (LNCaP) independent experi-
ments performed in triplicates ± SE. All data were analyzed
with Excel (Microsoft Inc.) and GraphPad Prism 5 soft-
ware. Analyzed data were plotted into graphs using the
GraphPad Prism 5 software (GraphPad Software, Inc.).
Gene expression analysis
Total RNA was isolated using Trizol (Invitrogen) or Tri-
Reagent (MRC, Inc) according to manufacturer’s pro-
tocols. RNA was subsequently reverse-transcribed using
the ‘High-capacity cDNA reverse transcription kit (Applied
Biosystems) according to manufacturer’s protocols. Real-
time (RT) qPCR was performed using the Rotor-Gene
3000 (Corbett Life Science, now Qiagen) and SYBR Green
kit (Bioline) according to manufacturer’s protocols using
the RT-qPCR primers listed in Additional file 12: Table S2.
Mean value ± SE was calculated and blotted into graphs
with GraphPad Prism 5 software (GraphPad Software).
Q-RT-PCR Primer sequences are shown in Additional
file 12: Table S2.
Luciferase reporter assays
Luciferase reporter assays were performed as previously
described [97] and according to manufacturer’s protocol
(Promega) using the dual luciferase assay kit (Promega)
and a TECAN infinite M200 luminometer (Tecan Systems).
Briefly, PC3 cells were seeded in 6-well plates at 0.4 × 106
cells/well and co-transfected with an IRF1-promoter-driven
luciferase reporter vector (500 ng DNA/ml) along with
expression vectors for DTX3L, ARTD9 and/or STAT1α/β
(800 ng DNA/ml) and with the control reporter plasmid,
pRL-hTK (100 ng/ml) (hTK-prom-renilla–luciferase con-
trol), and subsequently treated with or without IFNγ (200
U/ml) for 4 h. IRF1-promoter-luciferase activities were
normalized to the luciferase activities of the internal
hTK-prom-renilla-luciferase control and presented as mean
from five independent experiments performed in tripli-
cates. Statistical analysis was performed using the Student's
t test. *P < 0.05, **P < 0.001 and ***P < 0.0001. For siRNA
knockdown experiments, PC3 cells were co-transfected in
serious: first with mock-siRNA, STAT1-siRNA, DTX3L-
siRNA or ARTD9-siRNA and subsequently (24 h later)
with an IRF1-promoter-driven luciferase reporter vector
(500 ng DNA/ml) along with expression vectors for DTX
3L, ARTD9 and/or STAT1α/β (800 ng DNA/ml) and with
the control reporter plasmid, pRL-hTK (100 ng DNA/ml).
Scratch wound healing migration assay
DU145 or PC3 cells were seeded into 6-well plates
(0.2 × 106 cells/well) and transfected with siRNA as indi-
cated. After 24 h the cells were trypsinized and 400’000
cells were pooled into one well. After 24–36 h when
cells reached confluency, identical scratches were made
in parallel wells using a 1000 μl plastic pipette tip. Non-
adherent cells were removed by two washes. The closure
of the scratch was analyzed under the microscope and
images were captured at 0, 12, 24, and 36 h after incuba-
tion. Photographs were made with a Leica DMI6000B
automated inverted research microscope system (Leica
Microsystems) at indicated time points. The size of the
uncovered areas was measured with Adobe Photoshop
software and converted into percentages. For analysis of
the migration potential mean values of three independ-
ent experiments were analyzed. Mean value ± SE was
calculated and plotted into graphs with GraphPad Prism
5 software (GraphPad Software, Inc.).
Statistical analysis
Continuous variables were summarized as mean and SE.
Statistical evaluations (comparisons between control and
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treated groups) were established by Student's T-test for
unpaired data (for two comparisons). P values < 0.05 were
considered statistically significant. All statistical evalua-
tions were performed with GraphPad Prism 5 software
(GraphPad Software, Inc.).
Availability of supporting data
“The data set(s) supporting the results of this article is
(are) included within the article (and its additional file(s))”.
Additional files
Additional file 1: Figure S1. Quantification of ARTD9, DTX3L, IRF1,
STAT1 and pSTAT1 protein levels. (A) Quantification of ARTD9 and DTX3L
protein levels in PC3, DU145 and LNCaP cells, represented in Figure 1B.
ARTD9 and DTX3L protein levels were normalized to tubulin. (B)
Quantification of pSTAT1-Y701 and pSTAT1-S727 protein levels in PC3,
DU145 and LNCaP cells, represented in Figure 1B. pSTAT1-Y701 and
pSTAT1-S727 protein levels were normalized to tubulin and STAT1. All values
represent the means of three independent experiments, and the error bars
represent the SE. Statistical analysis was performed using the Student's t test.
*P < 0.05, **P < 0.001 and ***P < 0.0001. (C) Immunoblot analyses of STAT
signaling in PC3, DU145 and LNCaP cells treated with or without IFNγ (200
U/ml) or IFNαβ (50 U/ml each). Whole cell extracts were separated by SDS
PAGE and subsequently probed with antibodies for STAT1αβ, pSTAT1(Y701),
STAT2, pSTAT2(Y690), STAT3α, STAT3αβ, pSTAT3α(S727), STAT5αβ, pSTAT5
(S726), STAT6 and pSTAT6(Y641) and tubulin. (D) Immunoblot analyses of
ARTD8, ARTD9 and DTX3L levels in PC3-siMock and PC3-siJAK1 cells. Whole
cell extracts were separated by SDS PAGE, blotted and subsequently probed
with antibodies for JAK1, ARTD8, ARTD9, DTX3L and tubulin. (D right panel)
Analysis of JAK1- siRNA knockdown efficiency in PC3 cells; JAK1 protein
levels were normalized to tubulin. (E) Immunoblot analyses of ARTD9 and
DTX3L protein levels in PC3-siMock and PC3-siSTAT3 cells. Whole cell
extracts were separated by SDS PAGE, blotted and subsequently probed
with antibodies for ARTD9, DTX3L and tubulin. All immunoblots are
representative of at least three independent experiments. (E right panel)
Analysis of STAT3-siRNA knockdown efficiency in PC3 cells; Total RNA was
isolated from PC3-siMock, and PC3-siSTAT3 cells and STAT3 mRNA levels
were measured by RT-qPCR, normalized against GAPDH and presented as
mean from three independent experiments performed in triplicate ± SE.
Additional file 2: Figure S2. Sub-cellular localization of endogenous
STAT1 in DU145 and LNCaP cells and quantification of IRF1 protein levels
in PC3, DU145 and LNCaP cells. (A) Immunofluorescence microscopy
analyses and sub-cellular localization of endogenous STAT1, pSTAT1-(pY701)
and pSTAT1-(pS727) in DU145 cells, in presence or absence of 1000 U/ml
IFNγ. Original magnification × 400. Images are representative of at least
three independent experiments. (B) Immunofluorescence microscopy
analyses and sub-cellular localization of endogenous STAT1, pSTAT1-(pY701)
and pSTAT1-(pS727) in LNCaP cells. Original magnification × 400. Images are
representative of at least three independent experiments. (C) Quantification
of IRF1 protein levels in PC3, DU145 and LNCaP cells, as represented in
Figure 1C. IRF1 levels were normalized to tubulin. Values represent the
means of three independent experiments, and the error bars represent the
SE. Statistical analysis was performed using the Student's t test. *P < 0.05,
**P < 0.001 and ***P < 0.0001, according to the t-test analysis.
Additional file 3: Figure S3. Sub-cellular localization of endogenous
DTX3L and ARTD9 in PC3-siARTD9 or -siDTX3L knockdown cells,
respectively. (A) Immunofluorescence microscopy analyses and
sub-cellular localization of endogenous DTX3L and ARTD9 in PC3-siMock
(A), PC3-siDTX3L (B) and PC3-siARTD9 (C) knockdown cells in absence or
presence of IFNγ (200 U/ml). Original magnification × 400. Images are
representative of at least three independent experiments.
Additional file 4: Figure S4. Co-staining of endogenous DTX3L and
ARTD9 in PC3-siARTD9 or -siDTX3L knockdown cells, respectively.
(A) Co-staining and immunofluorescence microscopy analyses of
endogenous DTX3L and ARTD9 in PC3-siMock (A), PC3-siDTX3L (B) and
PC3-siARTD9 (C) knockdown cells in absence or presence of IFNγ (200 U/ml).
Cells were co-stained using a mouse monoclonal anti-DTX3L antibody (red)
together with a rabbit polyclonal anti-ARTD9 antibody (green). Original
magnification × 400.
Additional file 5: Figure S5. Quantifications of ARTD8-, ARTD9- and
DTX3L-siRNA knockdown efficiencies and analysis of ARTD8, ARTD9 and
DTX3L containing complexes. (A and B) Analysis of ARTD8, ARTD9
and DTX3L-siRNA knockdown efficiency in PC3 cells. (A) Gene expression
analysis of ARTD8, ARTD9 and DTX3L in PC3-siMock, PC3-siARTD8,
PC3-siARTD9 and PC3-siDTX3L cells, respectively. ARTD8, ARTD9 and
DTX3L mRNA levels were measured by RT-qPCR, normalized against
GAPDH and presented as mean from three independent experiments
performed in triplicate ± SE. (B) Quantification of ARTD8, ARTD9 and
DTX3L protein levels in in PC3-siMock, PC3-siARTD8, PC3-siARTD9 and
PC3-siDTX3L cells, respectively. ARTD8, ARTD9 and DTX3L levels were
normalized to tubulin. Values represent the means of three independent
experiments, and the error bars represent the SE. (C) Co-immunoprecipitation
control analyses to confirm the specificity of the anti- DTX3L antibody.
(D) Interactions of endogenous ARDT8 with ARTDs but not with DTX3L are
mediated by (mono)-ADP-ribosylation. Endogenous ARTD8-ARTDx and
ARTD8-DTX3L complexes from PC3 cell extracts were co-immunoprecipitated
in presence or absence of 5 mM mono-ADP-ribose using epitope affinity
purified anti-ARTD8 antibodies. Complexes were then separated on SDS
PAGE, blotted and subsequently probed with antibodies against endogenous
ARTD1, ARTD8, ARTD9, ARTD10 and DTX3L. ARTD1 was used as a positive
control for ARTD8 and ARTD9 [80] and ARTD10 was used as a positive control
for ARTD8 [44]. (E) Interactions of endogenous ARDT9 with ARTDs are
mediated by (mono)-ADP-ribosylation. PC3 cells were stimulated for 1 h with
IFNγ (200 U/ml) and endogenous ARTD9-ARTDx complexes subsequently
co-immunoprecipitated in presence or absence of 5 mM mono-ADP-ribose
using epitope affinity purified anti-ARTD9 antibodies. Complexes were then
separated on SDS PAGE, blotted and subsequently probed with antibodies
against endogenous ARTD9, ARTD10, ARTD12 (also known as PARP12) and
ARTD13 (also known as PARP13, ZAPS/L). (F) Co-immunoprecipitation control
analyses to confirm the specificity of the anti-ARTD9 antibody.
Additional file 6: Figure S6. Cell viability and proliferation analyses of
siDTX3L, siARTD8 and siARTD9 single knockdown cells. (A and B) Cell
viability analyses of PC3-siMock, PC3-siDTX3L cells silenced with si*1 or
si*2 RNA oligos (A) and PC3-siARTD9 cells silenced with si*1 or si*9 RNA
oligos (B) were assessed by the trypan blue exclusion assay. Cells were
treated as indicated with IFNγ and/or docetaxel (DT) and counted after
48 h. Values represent the means of three independent experiments, and
the error bars represent the SE. (C and D) Immunoblot analyses of
ARTD9- and DTX3L-siRNA knockdown efficiencies in DU145 cells. Whole
cell extracts were separated by SDS PAGE, blotted and subsequently
probed with antibodies for ARTD9 (C), DTX3L (D) and tubulin. (E) Cell
proliferation analyses of DU145-siMock, DU145-siDTX3L and DU145-siARTD9
single knockdown cells in presence or absence of IFNγ (200 U/ml) was
assessed by the trypan blue exclusion assay. (F) Cell viability analyses of
DU145-siMock, DU145-siDTX3L and DU145-siARTD9 knockdown cells were
assessed by the trypan blue exclusion assay. Cells were treated as indicated
with IFNγ and/or docetaxel (DT) and counted after 48 h, NT: not treated,
CT: control treatment (solvent). (G) Survival of PC3-siMock or PC3- siARTD8
knockdown cells, complemented with non-degradable mouse cDNAs of
active ARTD8 wild type or catalytically inactive ARTD8 mutant form,
respectively, were assessed by the trypan blue exclusion assay. Cells were
treated as indicated with docetaxel (DT) and/or with the ARTD inhibitor TIQ,
CT: control treatment (solvent), EV: empty vector control. All Values shown
in E to G represent the means of three independent experiments performed
in triplicates, and the error bars represent the SE. Statistical analysis was
performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
Additional file 7: Figure S7. Quantifications of STAT1-siRNA knockdown
efficiencies and IRF1 promoter analysis (A and B). Analysis of STAT1-siRNA
efficiency in PC3 cells. (A) Gene expression analysis of STAT1 in PC3-siMock
and PC3-siSTAT1 knockdown cells; Total RNA was isolated from PC3-siMock
and PC3-siSTAT1 knockdown cells and STAT1 mRNA levels were measured
by RT-qPCR and normalized against GAPDH. (B) Quantification of STAT1
protein levels in PC3-siMock and PC3-siSTAT1 knockdown cells; STAT1 levels
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were normalized to tubulin. (C) Gene expression analysis of IRF1 in
PC3-siMock, PC3-siARTD9 and PC3-siDTX3L knockdown cells. Total RNA was
isolated from PC3-siMock, PC3-siARTD9 and PC3-siDTX3L knockdown cells
and IRF1 mRNA levels were measured by RT-qPCR and normalized against
GAPDH. All Values shown in A to C represent the means of three independent
experiments, and the error bars represent the SE. (D) DTX3L- iRNA and
ARTD9-siRNA mediated activation of the IRF1-promoter driven luciferase in
PC3 cells. PC3 cells were co-transfected in series with mock-siRNA,
STAT1-siRNA, DTX3L-siRNA or ARTD9-siRNA and plasmids for an
IRF1-promoter-driven luciferase reporter vector as described in Material and
Methods and subsequently treated with or without IFNγ (200 U/ml) for 4 h.
(E-G) DTX3L and ARTD9 together with STAT1β inhibit the IRF1-promoter
driven luciferase in PC3 cells. PC3 cells were co-transfected with an
IRF1-promoter-driven luciferase reporter vector along with expression vectors
for DTX3L, ARTD9 and/or STAT1α/β and subsequently treated with or without
IFNγ (200 U/ml) for 4 h. IRF1-promoter-luciferase activities shown in D to G are
presented as mean from five independent experiments performed in
triplicates. The error bar represents the SE. Statistical analysis was performed
using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
Additional file 8: Figure S8. Quantifications of IRF1 protein levels,
quantifications of IRF1-siRNA knockdown efficiencies and cell viability
analysis of siIRF1 knockdown cells. (A) Immunoblot analyses of IRF1
protein levels in PC3-CMVprom-empty-control and PC3-CMVprom-IRF1
cells. Whole cell extracts of PC3-CMVprom-empty-control and
PC3-CMVprom7 IRF1 cells were separated by SDS PAGE, blotted and
probed with antibodies for IRF1 and tubulin. (A right panel) Quantification of
IRF1 protein levels in PC3-CMVprom-empty-control and PC3-CMVprom-IRF1
cells; IRF1 levels were normalized to tubulin. (B and C) Analysis of IRF1- siRNA
efficiency in PC3 cells. (B) Immunoblot analyses of IRF1 protein levels in
PC3-siMock and PC3-siIRF1 cells. Whole cell extracts of PC3-siMock and
PC3-siIRF1 cells were separated by SDS PAGE, blotted and probed with
antibodies for IRF1 and tubulin. (B right panel) Quantification of IRF1 protein
levels in PC3-simock and PC3-siIRF1 cells; IRF1 levels were normalized to
tubulin. (C) Gene expression analysis of IRF1 in PC3-siMock and PC3-siIRF1
knockdown cells. IRF1 mRNA levels were measured by RT-qPCR and
normalized against GAPDH. (D) Gene expression analysis of IRF1 in
LNCaP-siMock and LNCaP-siIRF1 knockdown cells. IRF1 mRNA levels were
measured by RT-qPCR and normalized against GAPDH. (E) Cell viability
analyses of PC3-siMock, PC3-siIRF1, PC3-siARTD9 and PC3-siARTD9/siIRF1 cells
were assessed by the trypan blue exclusion assay. Cells were treated as
indicated with 50 ng/ml IFNγ and 0.25 μM doxorubicin (D) and counted after
48 h and 72 h, respectively, NT: not treated, CT: control treatment (solvent).
All values shown in A to E represent the means of three independent
experiments, and the error bars represent the SE. Statistical analysis was
performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
(F) Co-immunoprecipitation analyses of endogenous nuclear DTX3L/ARTD9/
STAT1 complexes, respectively in PC3 cells. Endogenous STAT1, DTX3L or
RTD9 complexes were co-immunoprecipitated from nuclear extracts using
anti-ARTD9 antibodies and separated on SDS PAGE, blotted and probed with
antibodies for STAT1, DTX3L and ARTD9.
Additional file 9: Figure S9. Photographs and quantification of cell
migration in siARTD8, siARTD9 and siDTX3L single knockdown prostate
cancer cells. (A-D) Photographs of cell migration in PC3 prostate cancer
cells. PC3-siMock (A), PC3-siDTX3L (B), PC3-siARTD9 (C) and PC3-siARTD8
(D) single knockdown cells were seeded into 6-well plates and treated as
described in Material and Methods. At 0, 12, 24, and 36 h photographs were
made. (E and F) Quantification of cell migration in DU145 prostate cancer
cells. DU145-siDTX3L (E) and DU145-siARTD9 (F) single knockdown cells were
seeded into 6-well plates and treated as described in Material and Methods.
At 0, 12, 24, and 36 h photographs were made and quantified as described in
Material and Methods. Values represent the mean of three independent
experiments and the error bars represent the SE. Statistical analysis was
performed using the Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
Additional file 10: Figure S10. Photographs and quantification of cell
migration in single, double and triple knockdown prostate cancer cells.
(A-C) Photographs of cell migration in PC3 prostate cancer cells. PC3-siSTAT1
(A) PC3-siDTX3L/siSTAT1 (B) and PC3-siSTAT3 (C) single knockdown cells
were seeded into 6-well plates and treated as described in Material and
Methods. At 0, 12, 24, and 36 h photographs were made. (D-F) Quantification
of cell migration in PC3 and DU145 prostate cancer cells. PC3-siIRF1 (D),
DU145-siSTAT1 (E) and DU145-siSTAT3 (F) single knockdown cells,
DU145-siSTAT1/siSTAT3 (G) double knockdown cells and DU145-siDTX3L/
siSTAT1/siSTAT3 (H) triple knockdown cells were seeded into 6-well plates
and treated as described in Material and Methods. At 0, 12, 24, and 36 h
photographs were made and quantified as described in Material and
Methods. Values represent the mean of three independent experiments and
the error bars represent the SE. Statistical analysis was performed using the
Student's t test. *P < 0.05, **P < 0.001 and ***P < 0.0001.
Additional file 11: Table S1. siRNA sequences.
Additional file 12: Table S2. qPCR Primer.
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